User login
The smallest patients get a full day’s focus in the “Congenital Heart Disease Symposium: Innovations and Controversies in the Surgical Management of Congenital Heart Disease,” session on Sunday, April 30.
“This symposium is designed for participants to get up-to-date information about cardiothoracic surgery,” said Katsuhide Maeda, MD, of Stanford University Medical Center, in an interview.
The Pumps for Kids, Infants, and Neonates (PumpKIN) trial is designed as a randomized, multicenter, two-arm study to evaluate an investigational ventricular assistance device (VAD) known as Jarvik 2015, comparing it to the EXCOR Pediatric VAD in children with heart failure. The study is designed to enroll 88 patients, 44 randomized to the Jarvik 2015 and 44 to the EXCOR.
The primary objectives of the PumpKIN trial, according to Clinicaltrials.gov description, are to determine the safety of the Jarvik 2015 based on evaluations of reported serious adverse events up to the first 180 days after implantation, and to assess benefits based on overall survival without severe neurologic impairment.
Symposium attendees can learn the latest information about outcomes as well as tips and techniques for device use in neonates and infants, Dr. Maeda said.
Some of the presentations featuring tips and techniques include “Device Innovations and Options for Biventrical Mechanical Circulatory Support,” by Mark Shepard, MD, of St. Louis Children’s Hospital; “Surgical Techniques for TAPVR,” by Christopher A. Caldarone, MD, of the Hospital for Sick Children, Toronto; and “The “Tweener” Arch - Front vs. Side,” by Charles D. Fraser, MD, of Texas Children’s Hospital.
Looking ahead, Dr. Maeda advised clinicians to keep watching the PumpKIN trial, which is set to begin in seven institutions in the United States and Canada. “This device may open a new door,” for pediatric heart surgery, he noted.
The smallest patients get a full day’s focus in the “Congenital Heart Disease Symposium: Innovations and Controversies in the Surgical Management of Congenital Heart Disease,” session on Sunday, April 30.
“This symposium is designed for participants to get up-to-date information about cardiothoracic surgery,” said Katsuhide Maeda, MD, of Stanford University Medical Center, in an interview.
The Pumps for Kids, Infants, and Neonates (PumpKIN) trial is designed as a randomized, multicenter, two-arm study to evaluate an investigational ventricular assistance device (VAD) known as Jarvik 2015, comparing it to the EXCOR Pediatric VAD in children with heart failure. The study is designed to enroll 88 patients, 44 randomized to the Jarvik 2015 and 44 to the EXCOR.
The primary objectives of the PumpKIN trial, according to Clinicaltrials.gov description, are to determine the safety of the Jarvik 2015 based on evaluations of reported serious adverse events up to the first 180 days after implantation, and to assess benefits based on overall survival without severe neurologic impairment.
Symposium attendees can learn the latest information about outcomes as well as tips and techniques for device use in neonates and infants, Dr. Maeda said.
Some of the presentations featuring tips and techniques include “Device Innovations and Options for Biventrical Mechanical Circulatory Support,” by Mark Shepard, MD, of St. Louis Children’s Hospital; “Surgical Techniques for TAPVR,” by Christopher A. Caldarone, MD, of the Hospital for Sick Children, Toronto; and “The “Tweener” Arch - Front vs. Side,” by Charles D. Fraser, MD, of Texas Children’s Hospital.
Looking ahead, Dr. Maeda advised clinicians to keep watching the PumpKIN trial, which is set to begin in seven institutions in the United States and Canada. “This device may open a new door,” for pediatric heart surgery, he noted.
The smallest patients get a full day’s focus in the “Congenital Heart Disease Symposium: Innovations and Controversies in the Surgical Management of Congenital Heart Disease,” session on Sunday, April 30.
“This symposium is designed for participants to get up-to-date information about cardiothoracic surgery,” said Katsuhide Maeda, MD, of Stanford University Medical Center, in an interview.
The Pumps for Kids, Infants, and Neonates (PumpKIN) trial is designed as a randomized, multicenter, two-arm study to evaluate an investigational ventricular assistance device (VAD) known as Jarvik 2015, comparing it to the EXCOR Pediatric VAD in children with heart failure. The study is designed to enroll 88 patients, 44 randomized to the Jarvik 2015 and 44 to the EXCOR.
The primary objectives of the PumpKIN trial, according to Clinicaltrials.gov description, are to determine the safety of the Jarvik 2015 based on evaluations of reported serious adverse events up to the first 180 days after implantation, and to assess benefits based on overall survival without severe neurologic impairment.
Symposium attendees can learn the latest information about outcomes as well as tips and techniques for device use in neonates and infants, Dr. Maeda said.
Some of the presentations featuring tips and techniques include “Device Innovations and Options for Biventrical Mechanical Circulatory Support,” by Mark Shepard, MD, of St. Louis Children’s Hospital; “Surgical Techniques for TAPVR,” by Christopher A. Caldarone, MD, of the Hospital for Sick Children, Toronto; and “The “Tweener” Arch - Front vs. Side,” by Charles D. Fraser, MD, of Texas Children’s Hospital.
Looking ahead, Dr. Maeda advised clinicians to keep watching the PumpKIN trial, which is set to begin in seven institutions in the United States and Canada. “This device may open a new door,” for pediatric heart surgery, he noted.